Skip to main content

Lactobacillus acidophilus alleviates type 2 diabetes by regulating hepatic glucose, lipid metabolism and gut microbiota in mice.

  • 2019
  • Food & Function 10(9)
    • Fenfen Yan
    • Na Li
    • Jialu Shi
    • Huizhen Li
    • Yingxue Yue
    • Wenshu Jiao
    • Nana Wang
    • Yue Song
    • G. Huo
    • Bailiang Li

Abstract

Diabetes, an endocrine and metabolic disorder, has become the third most non-infectious chronic disease that threatens human health. Type 2 diabetes (T2D) accounts for more than 90% of diabetic patients, mainly caused by environmental factors. Lactic acid bacteria (LAB) exhibit several health benefits to the host including regulating glucose and lipid metabolism and improving oxidative stress and inflammatory response. However, the anti-diabetic mechanism of probiotics has not been elucidated clearly. In this study, the anti-diabetic effects of Lactobacillus acidophilus KLDS1.1003 and KLDS1.0901 on T2D mice were assessed. Oral administration of L. acidophilus KLDS1.1003 and KLDS1.0901 for 6 weeks significantly improved the epithelial barrier function, which in turn lowered inflammation cytokines, including IL-8, TNF-α and IL-1β in liver and colon tissue, and prevented liver and colon tissue injuries to some extent. Additionally, L. acidophilus treatment regulated the expression genes that are related to glucose and lipid metabolism. The two tested strains down-regulated the expression of glycogen synthase kinase 3β (GSK-3β), fatty acid synthase (FAS) and sterol regulatory element-binding transcription factor 1c (SREBP-1c), and up-regulated the expression of protein kinase B (Akt). However, L. acidophilus KLDS1.0901 is better for improving T2D than L. acidophilus KLDS1.1003. Further research showed that L. acidophilus KLDS1.0901 supplementation could reshape gut microbiota, increasing short chain fatty acid-producing bacteria (Blautia, Roseburia and Anaerotruncus) and the level of SCFAs and decreasing the relative abundance of Gram-negative bacteria such as Desulfovibrio, Alistipes and Bacteroides. Notably, L. acidophilus KLDS1.0901 treatment restored the structure of gut microbiota similar to the control group. These findings suggested that L. acidophilus KLDS1.0901 might be used as a new type of antidiabetic drug candidate.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus acidophilusAltered Gut MicrobiotaBeneficial
Moderate
Lactobacillus acidophilusImproved Epithelial Barrier FunctionBeneficial
Moderate
Lactobacillus acidophilusReduced Inflammatory CytokinesBeneficial
Moderate
Lactobacillus acidophilusRestored Gut Microbiota StructureBeneficial
Large
Lactobacillus acidophilus HA-122Altered Gut MicrobiotaBeneficial
Moderate
Lactobacillus acidophilus HA-122Improved Epithelial Barrier FunctionBeneficial
Moderate
Lactobacillus acidophilus HA-122Reduced Inflammation LevelsBeneficial
Moderate
Lactobacillus acidophilus LA1Altered Gut MicrobiotaBeneficial
Moderate
Lactobacillus acidophilus LA1Improved Epithelial Barrier FunctionBeneficial
Moderate
Lactobacillus acidophilus LA1Reduced Inflammation LevelsBeneficial
Moderate
Lactobacillus acidophilus MAK32L61AAltered Gut MicrobiotaBeneficial
Moderate
Lactobacillus acidophilus MAK32L61AImproved Epithelial Barrier FunctionBeneficial
Moderate
Lactobacillus acidophilus MAK32L61AImproved Insulin SensitivityBeneficial
Large
Lactobacillus acidophilus MAK32L61AReduced Inflammatory Cytokine LevelsBeneficial
Moderate
Lactobacillus acidophilus UALa01Altered Gut Microbiota CompositionBeneficial
Large
Lactobacillus acidophilus UALa01Improved Epithelial Barrier FunctionBeneficial
Moderate
Lactobacillus acidophilus UALa01Reduced Inflammatory ResponseBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.